TCI GENE Statistics
Total Valuation
TCI GENE has a market cap or net worth of TWD 965.74 million. The enterprise value is 114.86 million.
| Market Cap | 965.74M |
| Enterprise Value | 114.86M |
Important Dates
The next estimated earnings date is Thursday, March 5, 2026.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | Sep 5, 2025 |
Share Statistics
TCI GENE has 26.46 million shares outstanding. The number of shares has increased by 0.20% in one year.
| Current Share Class | 26.46M |
| Shares Outstanding | 26.46M |
| Shares Change (YoY) | +0.20% |
| Shares Change (QoQ) | -0.09% |
| Owned by Insiders (%) | 9.59% |
| Owned by Institutions (%) | 1.71% |
| Float | 4.39M |
Valuation Ratios
The trailing PE ratio is 27.03.
| PE Ratio | 27.03 |
| Forward PE | n/a |
| PS Ratio | 2.97 |
| PB Ratio | 1.04 |
| P/TBV Ratio | 1.07 |
| P/FCF Ratio | 10.21 |
| P/OCF Ratio | 9.94 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.00, with an EV/FCF ratio of 1.21.
| EV / Earnings | 3.21 |
| EV / Sales | 0.35 |
| EV / EBITDA | 2.00 |
| EV / EBIT | 2.55 |
| EV / FCF | 1.21 |
Financial Position
The company has a current ratio of 5.74, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.74 |
| Quick Ratio | 5.47 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.19 |
| Debt / FCF | 0.13 |
| Interest Coverage | 64.06 |
Financial Efficiency
Return on equity (ROE) is 3.42% and return on invested capital (ROIC) is 78.84%.
| Return on Equity (ROE) | 3.42% |
| Return on Assets (ROA) | 2.97% |
| Return on Invested Capital (ROIC) | 78.84% |
| Return on Capital Employed (ROCE) | 5.95% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.28 |
| Inventory Turnover | 3.16 |
Taxes
In the past 12 months, TCI GENE has paid 7.95 million in taxes.
| Income Tax | 7.95M |
| Effective Tax Rate | 18.91% |
Stock Price Statistics
The stock price has decreased by -29.81% in the last 52 weeks. The beta is 0.13, so TCI GENE's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -29.81% |
| 50-Day Moving Average | 36.72 |
| 200-Day Moving Average | 41.92 |
| Relative Strength Index (RSI) | 53.13 |
| Average Volume (20 Days) | 6,564 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TCI GENE had revenue of TWD 324.73 million and earned 35.80 million in profits. Earnings per share was 1.35.
| Revenue | 324.73M |
| Gross Profit | 186.94M |
| Operating Income | 55.42M |
| Pretax Income | 42.03M |
| Net Income | 35.80M |
| EBITDA | 61.93M |
| EBIT | 55.42M |
| Earnings Per Share (EPS) | 1.35 |
Balance Sheet
The company has 883.95 million in cash and 12.57 million in debt, with a net cash position of 871.39 million or 32.93 per share.
| Cash & Cash Equivalents | 883.95M |
| Total Debt | 12.57M |
| Net Cash | 871.39M |
| Net Cash Per Share | 32.93 |
| Equity (Book Value) | 928.38M |
| Book Value Per Share | 34.31 |
| Working Capital | 830.10M |
Cash Flow
In the last 12 months, operating cash flow was 97.15 million and capital expenditures -2.61 million, giving a free cash flow of 94.55 million.
| Operating Cash Flow | 97.15M |
| Capital Expenditures | -2.61M |
| Free Cash Flow | 94.55M |
| FCF Per Share | 3.57 |
Margins
Gross margin is 57.57%, with operating and profit margins of 17.07% and 11.02%.
| Gross Margin | 57.57% |
| Operating Margin | 17.07% |
| Pretax Margin | 12.94% |
| Profit Margin | 11.02% |
| EBITDA Margin | 19.07% |
| EBIT Margin | 17.07% |
| FCF Margin | 29.12% |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 5.74%.
| Dividend Per Share | 2.00 |
| Dividend Yield | 5.74% |
| Dividend Growth (YoY) | -33.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 73.91% |
| Buyback Yield | -0.20% |
| Shareholder Yield | 5.28% |
| Earnings Yield | 3.71% |
| FCF Yield | 9.79% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TCI GENE has an Altman Z-Score of 6.35 and a Piotroski F-Score of 4.
| Altman Z-Score | 6.35 |
| Piotroski F-Score | 4 |